Nicotine vaccine

The aim of nicotine vaccines is to prevent smoking relapse. Past studies discovered that the region ventral tegmental area (VTA) in which the dopaminergic neurons are located, is where nicotine binds to and activates its nAChR receptor, resulting in the release of dopamine. Aside from dopamine release, there are additional neurotransmitters released, which include norepinephrine, acetylcholine, serotonin, γ-aminobutyric acid (GABA), glutamate, and endorphins. Tobacco, the use of which is considered by the World Health Organization to be a global epidemic, contains the highly addictive substance nicotine. The increased dopamine level increases which results in drug dependence, in which smokers often face difficulties during the process of nicotine withdrawal. experienced and reported by smokers, such as arousal, improved performance, pleasure and improved moods, which are all desired psychological states. Nicotine withdrawal symptoms include anxiety, stress, irritability, depressed mood, difficulty concentrating, increased sense of hunger, increased eating, insomnia, and addiction to tobacco. Smokers that encounter these negative withdrawal symptoms choose to avoid such negative experiences and smoke tobacco again for the relief of nicotine withdrawal symptoms, resulting in relapse. == Formulation ==

The constitution of nicotine vaccines involves the addition of adjuvants to the conjugation between synthetic drug-derived haptens The carrier proteins used are all able to produce an immune response. == Mechanism of action ==

Nicotine, an addictive natural substance present in tobacco, works as an agonist for the nicotinic acetylcholine receptor (nAChR). Pharmaceutical vaccine haptens attempt to imitate the structure of nicotine since the metabolites of nicotine (half-life of nicotine = 1–2 hours) are less physiologically active than the parent compound. Conjugated immunogens are injected to deliver the vaccine, which activates B and T cells in a T cell-dependent manner to create polyclonal anti-nicotine antibodies. The conjugated vaccine is exposed to lymphocytes by antigen-presenting cells. There is recognition of the peptide antigen by T-cell receptors. With the involvement of cytokines and B cells, a humoral response The explanation for this is that when anti-nicotine antibodies bind to the nicotine molecules there is an increase in the overall molecular size. This blocks it from passing through the blood-brain barrier, and so nicotine is unable to generate the multiple neurotransmitters to exhibit its CNS effects.This prevents the synthesis of adrenaline and dopamine, which are the associated rewarding CNS effects that cause addiction, thereby inhibiting the pharmacological effects of nicotine. == Alternatives for smoking cessation ==

Only nicotine replacement (patches or gum), the antidepressant bupropion, and the nicotinic receptor agonist varenicline are approved to help tobacco users reduce their smoking while managing their addiction. However, less than one-third of the treatment receivers had quit, and only one-third of them succeeded in quitting for more than six months. Furthermore, more than half of those who received smoking cessation medication returned. New strategies are required to solve this significant health issue in the midst of these obstacles in order to promote smoking cessation. Immunotherapy-based methods, such as the use of vaccines to treat addiction, have been documented in the literature since the 1960s and 1970s. A number of researchers re-evaluated the immunizations as side effects linked to licensed nicotine replacement therapy use have arisen. Due to their capacity to generate high-affinity anti-drug IgG antibodies, conjugate vaccines show potential as an alternative method of treating drug use disorders. Although the use of nicotine vaccines may produce high levels of anti-nicotine antibodies to bind to all nicotine molecules and reduce the nicotine's effects on the brain by inhibiting its distribution, the dissociation rate constant (Kd) will determine whether there is a possibility of reversing the binding. == Dosage ==

A total of three priming injections spaced 2–4 weeks apart are typically used in the conjugate vaccination regimen. The function of antibodies is dependent on two factors. The first factor is "titer", which refers to the number of antibodies present, and the second factor is the "affinity" of the anti-nicotine antibody to the nicotine. Peak titer levels are reached between 2–4 weeks after a single injection and then begin to drop until a booster injection is given for the maintenance of nicotine antibody levels, due to the degradation Although infectious disease vaccines can be useful for many years without injecting boosters, drug vaccines are likely to require shorter booster intervals of one year or less. The purpose of the use of a booster is different from the mechanism of the first vaccination of the nicotine-conjugate vaccine. The first vaccination marks the immune system's initial contact with the antigen, which is how immunological memory functions. The booster vaccines are for the production of antibodies which utilize the immune system's memory regarding the encounter with antigens. This methodology will allow booster vaccines to generate a more rapid and efficient response to the antigen. == Adverse effects ==

Clinical studies with cocaine and nicotine, which commonly used doses of 200 or 400 micrograms per dose, have shown convincing evidence that doses of immunobinding agents, even up to 2 mg per dose, are positively correlated with titer levels. Since there was no ceiling effect, these findings imply that the optimal dose was the highest dose of the vaccine that can be administered without causing adverse reactions. So far, no clinical conjugate vaccine studies have found any major adverse reactions to drug or vaccine conjugates. == Pros and cons ==

The preferred technique for treating drug use disorders is active immunization because it is relatively safe and convenient in that the effect lasts even after several doses of the vaccine. Compared to small molecule medications, vaccines have a much-extended duration of action because they generate IgG antibodies with a longer half-life. Conjugated vaccines act as immune antagonists that hinder the efficacy of the target substances. The anti-drug antibodies do not affect drug receptors in the brain or periphery, and therefore, the side effects are negligible. One additional advantage of conjugate vaccines is that they are universal and can be created to target any single drug or drug combinations in theory. Despite having long-lasting impacts, the vaccination strategy's antibody response is comparatively slow. The effectiveness of the active vaccination method in changing behavior has not been established. They do not lessen withdrawal signs or drug cravings. == Efficacy ==

Animal trials To produce antibodies to measure nicotine amounts in human blood and urine, a trans-3′-succinimidylmethyl nicotine conjugate was coupled to KLH and administered to rabbits. It has been demonstrated that a completely synthetic nicotine vaccine (SEL-068) that contains an unidentified hapten prevents nicotine discrimination in non-human primates. Human clinical trials The results of several vaccine candidates that have reached human trials have, generally speaking, been discouraging. Positive findings from phase II trials showed strong antibody outcomes and higher quit percentages in the treatment group in comparison to the placebo group. In trials, the Niccine tetanus toxoid conjugate vaccine, which had an acceptable safety profile, demonstrated a comparable impact without altering smokers' habits. NIC-002 contained nicotine conjugated to virus-like particles, also failed to achieve major clinical endpoints in the trial. It showed a marginally higher rate of smoking cessation at the two months but no change at the six months. TA-NIC was withdrawn since it failed to reach its clinical endpoints. Despite many clinical trials, there is still a lack of evidence that supports vaccines as the effective solution to preventing drug abuse. Low antibody responses, short-lived antibody responses, individual differences in antibody responses, and continued substance use in the presence of an antibody response contribute to the undesired efficacy. == References ==